United Therapeutics CEO Executes 10b5-1 Plan; 8,000 Shares Sold Near $398
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corporation (UTHR), reported option exercises and concurrent sales under a pre-arranged 10b5-1 trading plan. On 09/10/2025 and 09/11/2025 she exercised 4,000 stock options each day at an exercise price of $120.26 per share, resulting in 8,000 shares acquired. Those 8,000 shares were sold the same two days in multiple trades at weighted-average prices of approximately $397–$399, generating the reported sales of 8,000 shares.
Following these transactions, the filing shows direct beneficial ownership lines with small net share changes and indicates remaining stock options outstanding: 282,000 and 278,000 shown after the two exercises, and a tranche of 294,000 options subject to the 10b5-1 plan that expire on March 15, 2026. The 10b5-1 plan was entered May 2, 2025 and will continue until the tranche is exhausted or December 31, 2025.
Positive
- Transactions executed under a documented 10b5-1 trading plan entered May 2, 2025, demonstrating pre-arranged compliance
- Clear disclosure of indirect holdings via spouse and family trusts, including specific share counts and trust roles
Negative
- Reported sales of 8,000 shares at weighted-average prices near $397–$399 reduced directly held shares
- Significant remaining option tranche (294,000 options) expires March 15, 2026, which could lead to additional insider exercises/sales before expiration
Insights
TL;DR: CEO exercised 8,000 options and sold the resulting shares under a 10b5-1 plan, realizing proceeds at ~ $397–$399 per share.
The transactions are routine insider liquidity actions executed pursuant to a pre-established 10b5-1 plan dated May 2, 2025. The filing documents exercises at the $120.26 exercise price and contemporaneous sales at weighted-average prices near $397–$399, indicating a material spread between exercise cost and sale proceeds. The filing also discloses remaining option tranches and specific trust holdings, which preserve the reporting person’s substantial indirect stake. For investors, these are disclosure of insider activity rather than new corporate events; no new debt, capital raises, or corporate actions are reported in this form.
TL;DR: Insider trading was executed under a documented 10b5-1 plan, and the filing properly discloses trust and spousal holdings.
The report indicates compliance with Rule 10b5-1 by identifying the trading plan and providing post-transaction beneficial ownership figures. It also clarifies the nature of indirect holdings through family trusts and spouse arrangements. The disclosure of weighted-average sale prices and the plan termination conditions (exhaustion of a 294,000-option tranche or December 31, 2025) adds useful specificity for governance transparency. No departures from standard Section 16 reporting practices are indicated.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 4,000 | $397.226 | $1.59M |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 2,000 | $398.11 | $796K |
| Sale | Common Stock | 2,000 | $399.3264 | $799K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $397.72 to $398.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $399.09 to $399.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $396.97 to $397.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
